28200 Effects of ruxolitinib cream on work productivity and activity impairment in patients with atopic dermatitis: Pooled results from two phase 3 studies

Abstract

Atopic dermatitis (AD) is a chronic inflammatory skin disease that can negatively impact work productivity and daily activities. Ruxolitinib cream is a Janus kinase (JAK) 1/JAK2 inhibitor in development for AD. In two randomized phase 3 studies (TRuE-AD1 [NCT03745638]; TRuE-AD2 [NCT03745651]) that enrolled patients aged ≥12 years with AD for ≥2 years, an Investigator’s Global Assessment score of 2 or 3, and 3%–20% affected body surface area, ruxolitinib cream was well tolerated and showed anti-inflammatory and antipruritic effects. Here, patient-reported outcomes using the Work Productivity and Activity Impairment Questionnaire-Specific Health Problem version 2.0 (WPAI:SHP v2.0) are reported for all employed patients. Patients (N = 1249 total; median age, 32 years) were randomized (2:2:1) to twice-daily 0.75% ruxolitinib, 1.5% ruxolitinib, or vehicle cream for 8 weeks of double-blind treatment. At Week 8, patients on ruxolitinib (0.75%/1.5%) reported less mean percentage of work time missed (absenteeism) due to AD (7.7%/7.5%; 7.9%/3.9% at baseline) vs vehicle (12.7%; 5.2% at baseline) and significantly greater reductions (mean change from baseline) in impairment while working with AD (presenteeism; –19.2/–19.8) vs vehicle (–12.3; both P ˂ .0001). The percentage of overall impairment due to AD (absenteeism and presenteeism) was also lower for 0.75%/1.5% ruxolitinib (14.3%/15.5%; 33.6%/31.8% at baseline) vs vehicle (31.0%; 36.4% at baseline) at Week 8. Ruxolitinib treatment (0.75%/1.5%) also resulted in significantly greater reductions in daily activity impairment scores (–20.6/–21.5) vs vehicle (–10.6; both P ˂ .0001) at Week 8. In summary, ruxolitinib cream brought about substantial improvements in daily activity and work productivity.